Posted by Michael Wonder on 14 Sep 2021
A court decision on “skinny labeling” another challenge for less expensive drugs
13 September 2021 - Brand name drugs, such as apixaban (Eliquis) and lenalidomide (Revlimid), account for approximately 80% of US drug spending during periods of market exclusivity protected by patents.
The only meaningful relief occurs when enough generic manufacturers enter the market to drive prices down to close to the cost of production.
To forestall generic entry, brand name manufacturers often obtain additional patents that cover aspects of the drug’s formulation and method of use.
